FMP
Rubius Therapeutics, Inc.
RUBY
NASDAQ
Inactive Equity
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
0.057 USD
0.0015 (2.63%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Laurence A. Turka M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.rubiustx.comexchange
NASDAQ
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
CIK
0001709401
ISIN
US78116T1034
CUSIP
78116T103
Address
399 Binney Street
Phone
617 679 9600
Country
US
Employee
6
IPO Date
Jul 18, 2018
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
RUBY Financial Summary
CIK
0001709401
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
78116T103
ISIN
US78116T1034
Country
US
Price
0.06
Beta
2.21
Volume Avg.
99.53k
Market Cap
0
Shares
-
52-Week
0.0032-0.3763
DCF
0.15
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.03
P/B
-
Website
https://www.rubiustx.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest RUBY News
It looks like there's no news available.
